Biogen pays $7.3B to acquire Reata and newly approved Skyclarys - FiercePharma

1. Biogen pays $7.3B to acquire Reata and newly approved Skyclarys  FiercePharma
2. Biogen to buy rare-disease drugmaker Reata in $7.3B deal  Yahoo Finance
3. Biogen Stock: Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals  Investor's Business Daily
4. Biogen Deal for Reata Signals a Turn to Rare Diseases  Bloomberg
5. Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition  Forbes
6. View Full Coverage on Google News